NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis → Write this ticker symbol down… (From StocksToTrade) (Ad) Free ATXI Stock Alerts $3.71 +0.31 (+9.12%) (As of 06/14/2024 08:50 PM ET) Add Compare Share Share Today's Range$3.25▼$3.7450-Day Range$3.38▼$11.5152-Week Range$3.25▼$93.75Volume24,600 shsAverage Volume70,822 shsMarket Capitalization$3.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrends Get Avenue Therapeutics alerts: Email Address Avenue Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish5.96% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.31 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Avenue Therapeutics.Read more about Avenue Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.96% of the float of Avenue Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvenue Therapeutics does not currently pay a dividend.Dividend GrowthAvenue Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvenue Therapeutics has received a 73.16% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Avenue Therapeutics is -0.99. Previous Next 2.5 News and Social Media Coverage News SentimentAvenue Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Avenue Therapeutics this week, compared to 10 articles on an average week.Search Interest8 people have searched for ATXI on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows3 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Avenue Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.34% of the stock of Avenue Therapeutics is held by institutions.Read more about Avenue Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Avenue Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avenue Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvenue Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Avenue Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About Avenue Therapeutics Stock (NASDAQ:ATXI)Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Read More ATXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXI Stock News HeadlinesMay 29, 2024 | msn.comBPD: Body recovered from canal near Q Street and California AvenueMay 29, 2024 | msn.comVehicle fire reported on Walnut Avenue in CarmichaelMay 29, 2024 | msn.comHFR: Multiple units respond to house fire on 10th Avenue SWMay 28, 2024 | msn.comA portion of Indiana Avenue in Sheboygan is closed. Here's how long construction is expected to last.May 28, 2024 | finance.yahoo.comThe CAA Worst Road in Ontario is Hamilton's Aberdeen AvenueMay 28, 2024 | msn.comPickup truck drives into house on Suffolk AvenueMay 28, 2024 | msn.comFour cars involved in crash on 390 near Lexington AvenueMay 28, 2024 | msn.comDelhi's Rouse Avenue Court summons minister Atishi in a defamation caseMay 28, 2024 | msn.comRenovations to building at Main Street and Clinton Avenue to begin: What will be in there?May 27, 2024 | msn.comLogan Avenue warehouse burns early Monday, residents should expect smoke: WFPSMay 27, 2024 | msn.comNew Berlin crash; 1 dead, 3 others hurt on W. National AvenueMay 27, 2024 | yahoo.com1 person dead after crash on Atlantic Avenue in Delray BeachMay 16, 2024 | globenewswire.comAvenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)May 15, 2024 | investorplace.comATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024May 15, 2024 | globenewswire.comAvenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 3, 2024 | msn.comMultiple lane closures coming to Capitol Avenue in downtown IndyMay 3, 2024 | msn.comPickup truck hits girl, flees the scene on Lamar AvenueMay 2, 2024 | msn.com2 people in critical condition after shooting on Arlington Avenue in ChattanoogaMay 2, 2024 | msn.comCrash with injuries, entrapment reported on Hamilton Avenue in Springfield TownshipMay 2, 2024 | msn.comMelrose Avenue record shop celebrates vinyl albums, takes music collectors on a journey through timeMay 2, 2024 | msn.comBrickell Avenue is the priciest commercial street in MiamiMay 2, 2024 | msn.comMilwaukee's National Avenue will see its auto lanes cut. Other safety changes are comingMay 2, 2024 | msn.comCity Avenue in Lower Merion set to triple its apartment count, transforming the office and retail hubMay 2, 2024 | msn.comGirl critically injured in hit-and-run on Lamar AvenueMay 2, 2024 | msn.com'It's wholesome': Houston Avenue church to host gospel rap concert to spread love in communitySee More Headlines Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/16/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATXI CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees3Year Founded2015Profitability EPS (Most Recent Fiscal Year)($7.8817) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,380,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-391.98% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book1.93Miscellaneous Outstanding Shares940,000Free Float924,000Market Cap$3.49 million OptionableNot Optionable Beta-0.10 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Alexandra MacLean M.D. (Age 57)CEO & Director Comp: $413.2kMr. David Jin (Age 34)Interim CFO, COO & Corporate Secretary Dr. Lindsay Allan Rosenwald (Age 69)Executive Director Dr. Scott A. Reines M.D. (Age 77)Ph.D., Interim Chief Medical Officer Comp: $69.12kKey CompetitorsGuardion Health SciencesNASDAQ:GHSIRedHill BiopharmaNASDAQ:RDHLImunonNASDAQ:IMNNElevai LabsNASDAQ:ELABVaccinexNASDAQ:VCNXView All CompetitorsInsidersFortress Biotech, Inc.Bought 5,578 shares on 9/8/2023Total: $301,212.00 ($54.00/share)Lindsay A Md RosenwaldBought 4,649 shares on 9/8/2023Total: $251,046.00 ($54.00/share)View All Insider Transactions ATXI Stock Analysis - Frequently Asked Questions Should I buy or sell Avenue Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXI shares. View ATXI analyst ratings or view top-rated stocks. How have ATXI shares performed in 2024? Avenue Therapeutics' stock was trading at $12.0750 on January 1st, 2024. Since then, ATXI stock has decreased by 69.3% and is now trading at $3.71. View the best growth stocks for 2024 here. Are investors shorting Avenue Therapeutics? Avenue Therapeutics saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 49,500 shares, an increase of 7.4% from the May 15th total of 46,100 shares. Based on an average daily volume of 61,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 6.0% of the shares of the stock are sold short. View Avenue Therapeutics' Short Interest. When is Avenue Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ATXI earnings forecast. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) issued its quarterly earnings results on Wednesday, May, 15th. The company reported ($15.40) earnings per share (EPS) for the quarter. When did Avenue Therapeutics' stock split? Avenue Therapeutics's stock reverse split on the morning of Friday, April 26th 2024. The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO). When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATXI) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.